Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
By Xiaobo Yang, Yuan Yu, Jiqian Xu, Huaqing Shu, Jia’an Xia, Hong Liu, Yongran Wu, Lu Zhang, Zhui Yu, Minghao Fang and 6 more. The Lancet Respiratory Medicine, 2020
8,377 citations recorded by the source corpus.
Background An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in December, 2019, in Wuhan, China. Information about critically ill patients with SARS-CoV-2 infection is scarce. We aimed to describe the clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia. Methods In this single-centered, retrospective, observational study, we enrolled 52 critically ill adult patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital (Wuhan, China) between late December, 2019, and Jan 26, 2020. Demographic data, symptoms, laboratory values, comorbidities, treatments, and clinical outcomes were all collected. Data were compared between survivors and non-survivors. The primary outcome was 28-day mortality, as of Feb 9, 2020. Secondary outcomes included incidence of SARS-CoV-2-related acute respiratory distress syndrome (ARDS) and the proportion of patients requiring mechanical ventilation. Findings Of 710 patients with SARS-CoV-2 pneumonia, 52 critically ill adult patients were included. The mean age of the 52 patients was 59·7 (SD 13·3) years, 35 (67%) were men, 21 (40%) had chronic illness, 51 (98%) had fever. 32 (61·5%) patients had died at 28 days, and the median duration from admission to the intensive care unit (ICU) to death was 7 (IQR 3–11) days for non-survivors. Compared with survivors, non-survivors were older (64·6 years [11·2] vs 51·9 years [12·9]), more likely to develop ARDS (26 [81%] patients vs 9 [45%] patients), and more likely to receive mechanical ventilation (30 [94%] patients vs 7 [35%] patients), either invasively or non-invasively. Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax. 37 (71%) patients required mechanical ventilation. Hospital-acquired infection occurred in seven (13·5%) patients. Interpretation The mortality of critically ill patients with SARS-CoV-2 pneumonia is considerable. The survival time of the non-survivors is likely to be within 1–2 weeks after ICU admission. Older patients (>65 years) with comorbidities and ARDS are at increased risk of death. The severity of SARS-CoV-2 pneumonia poses great strain on critical care resources in hospitals, especially if they are not adequately staffed or resourced. Funding None.
Subfields: Infectious Diseases, Neurology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/eb3e69649d0fa7972349b786375802ef3f6f67fe
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Neurology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (2020, neutral): “6]); and (6) critically ill patients in shock usually present limited gastrointestinal absorption, and no intravenous drug was available.”
- Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study (2020, neutral): “especially critical patients are susceptible to multiple organ dysfunction[16].”
- Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis (2020, methodology): “2020 [28] China/Wuhan Retrospective study from late December, 2019, and Jan 26, 2020.”
- Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. (2020, background): “Time from symptom onset to ICU admission, median (IQR), d 7 (4-10) 8 (5-10) 7 (3-9) Coexisting conditionsc”
- Biomarkers associated with COVID-19 disease progression (2020, background): “A significant increase in total bilirubin and CK, together with serum ferritin, WBC count, and IL-6 was registered in non-survivors compared to survivors [20,26,61].”
- Laboratory diagnosis of emerging human coronavirus infections – the state of the art (2020, result): “In contrast, a study of hospitalized patients (median age 47.5 years) across Beijing showed [8, 20, 22, 59] 18% of cases to be severe and 73% mild, with a fatality rate of 0.9% [19] .”
- Deployment of convalescent plasma for the prevention and treatment of COVID-19. (2020, neutral): “The risks of COVID-19 infection are profound (50, 51).”
- Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. (2020, neutral): “Length of hospital stay, median (IQR), d 22 (12-42) 12 (8-19) 39 (24-61) 79 (74-84) <.”